Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
WASHINGTON (AP) — Defense Secretary Lloyd Austin committed Monday to keeping U.S. weapons moving to2024-05-21NPR suspends whistleblower who exposed taxpayer
NPR has suspended a whistleblower editor who exposed the network's liberal bias, as its chief grappl2024-05-21Jon Bon Jovi says son Jake and future daughter
Jon Bon Jovi expressed his excitement about his son Jake and soon-to-be daughter-in-law Millie Bobby2024-05-21Red Wings miss playoffs despite 5
MONTREAL (AP) — Patrick Kane scored the shootout winner in a 5-4 Detroit win over the Montreal Canad2024-05-21With Djokovic awaiting the winner, Murray trails Hanfmann at rain
GENEVA (AP) — Needing a win to face Novak Djokovic next at the Geneva Open, Andy Murray was saved by2024-05-21Taylor Swift's New Heights Coachella cap is back in stock
Travis Kelce has wasted no time getting his New Heights caps back in stock on his podcast's website2024-05-21
atest comment